Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Journal of Pharmaceutical Health Services Research(2)
Drug Safety(1)
PLoS ONE(1)
Revista Panamericana de Salud Publica/Pan American Journal of Public Health(1)
The BMJ(1)
Área temáticas
Farmacología y terapéutica(5)
Producción(4)
Medicina y salud(3)
Enfermedades(1)
Otros problemas y servicios sociales(1)
Origen
scopus(7)
Correction to: A Landscape Analysis of Post-Marketing Studies Registered in the EU PAS Register and ClinicalTrials.gov Focusing on Pregnancy Outcomes or Breastfeeding Effects: A Contribution from the ConcePTION Project (Drug Safety, (2022), 45, 4, (333-344), 10.1007/s40264-022-01154-7)
OtherAbstract: In the original version of this article, the given and family names of “Leonardo Roque Pereira” werePalabras claves:Autores:Carlos E. Durán, Kontogiorgis C., Lalagkas P.N., Layton D., Pereira L.R., Poulentzas G., Sturkenboom M.C.J.M.Fuentes:scopusEMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
OtherAbstract:Palabras claves:Autores:Cañás M., Carlos E. Durán, Chistiaens T.Fuentes:scopusImpact of the European Union on access to medicines in low- and middle-income countries: A scoping review
ReviewAbstract: This Scoping Review synthesises evidence of the impacts of European Union (EU) law, regulation, andPalabras claves:Autores:Carlos E. Durán, de Ruijter A., Demchenko I., Mazzanti V., Parwani P., Perehudoff K., Suleman F.Fuentes:scopusSharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010–2014) consumption of oncologic drugs in public and private hospitals
ArticleAbstract: Objective: In Ecuador, a new constitutional mandate (2008) allowed the government to implement freePalabras claves:Cáncer, drug utilization, ECUADOR, health expenditures, Latin America, molecular targeted therapy, oncologic drugsAutores:Carlos E. Durán, Christiaens T., Elseviers M., Rottey S., Vander Stichele R.Fuentes:scopusRegulatory reliance to approve new medicinal products in Latin American and Caribbean countries
ArticleAbstract: Objective. To describe the current status of regulatory reliance in Latin America and the CaribbeanPalabras claves:Caribbean Region, Drug approval, Government Agencies, Latin America, Pan american health organization, Pharmaceutical preparations, United States Food and Drug AdministrationAutores:Andia T., Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.Fuentes:scopusPolicies influencing access to new targeted oncologic drugs in Ecuadorian hospitals: an interrupted time series analysis
ArticleAbstract: Objective and methods: An interrupted time series analysis was performed to measure the impact of twPalabras claves:antineoplastic drugs, drug and therapeutic committees, drug policies, ECUADOR, interrupted time series analysis, molecular targeted therapyAutores:Carlos E. Durán, Christiaens T., Elseviers M., Patricia Granja, Rottey S., Vander Stichele R.Fuentes:scopusPotential negative impact of reputed regulators decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis
ArticleAbstract: Background Many new cancer drugs are being approved by reputed regulatory authorities without evidenPalabras claves:Autores:Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.Fuentes:scopus